Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics
Quan Li, Jiancheng Hu · 2026
Read Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics by Quan Li, Jiancheng Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13562304.txt.
Description
Quan Li and Jiancheng Hu review a rare blood disorder in a 2026 paper on Langerhans cell histiocytosis. The disease is a non-inherited cancer-like growth driven by changes in one signaling pathway, most often in the BRAF gene. The review explains how each class of change keeps the pathway switched on.
The common mutation locks BRAF active on its own. Rarer forms vary: some are weak alone and work by pairing with a partner protein. Changes in the next pathway link break its self-braking or force pairing. Drugs that block BRAF or its partner help many patients, but resistance grows as the pathway reawakens through pairing tricks. The authors map next-generation drug ideas against those escape routes.
Catalog record
| CREATOR | Quan Li, Jiancheng Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |